Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Net Cash Flow (2016 - 2025)

Northwest Biotherapeutics' Net Cash Flow history spans 16 years, with the latest figure at -$2.1 million for Q4 2025.

  • Quarterly results put Net Cash Flow at -$2.1 million for Q4 2025, up 51.8% from a year ago — trailing twelve months through Dec 2025 was $2.7 million (up 320.63% YoY), and the annual figure for FY2025 was $2.7 million, up 320.63%.
  • Net Cash Flow for Q4 2025 was -$2.1 million at Northwest Biotherapeutics, up from -$2.8 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $10.9 million in Q4 2021 to a low of -$9.1 million in Q1 2022.
  • The 5-year median for Net Cash Flow is -$672000.0 (2021), against an average of -$635200.0.
  • The sharpest move saw Net Cash Flow soared 2662.04% in 2023, then crashed 5700.0% in 2024.
  • Year by year, Net Cash Flow stood at $10.9 million in 2021, then tumbled by 96.85% to $342000.0 in 2022, then tumbled by 965.79% to -$3.0 million in 2023, then crashed by 45.8% to -$4.3 million in 2024, then surged by 51.8% to -$2.1 million in 2025.
  • According to Business Quant data, Net Cash Flow over the past three periods came in at -$2.1 million, -$2.8 million, and $5.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.